Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription 08.04.2024 2 BJU Int 1 BMC Cancer 2 BMC Urol 1 Cancer Imaging 2 Eur Urol 1 Int J Radiat Oncol Biol Phys 3 Int J Urol 3 J Nucl Med 1 Oncogene 1 Oncol Rep 1 PLoS One 1 Proc Natl Acad Sci U S A 5 Prostate 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. TAKAHASHI T
   Endpoint and control group in prostate cancer screening research: public health basics.
   BJU Int. 2024 Mar 29. doi: 10.1111/bju.16356.
   PubMed        
   
   
2. ALBERTSEN PC
   Response to 'Endpoint and control group in prostate cancer screening research: public health basics'.
   BJU Int. 2024 Mar 30. doi: 10.1111/bju.16357.
   PubMed        
   
   

   
   BMC Cancer

3. AYOUB HM, Zamzam ML, Elsemary EE, Hassanin IM, et al
   Correction: Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy.
   BMC Cancer. 2024;24:419.
   PubMed        
   
   

   
   BMC Urol

4. WU F, Huang F, Jiang N, Su J, et al
   Identification of ferroptosis related genes and pathways in prostate cancer cells under erastin exposure.
   BMC Urol. 2024;24:78.
   PubMed         Abstract available
   
   
5. CHENG Y, Fan B, Fu Y, Yin H, et al
   Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram.
   BMC Urol. 2024;24:76.
   PubMed         Abstract available
   
   

   
   Cancer Imaging

6. KOLADE OU, Brink A, Ayeni AO, More S, et al
   Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
   Cancer Imaging. 2024;24:46.
   PubMed         Abstract available
   
   

   
   Eur Urol

7. ROY S, Fervaha G, Spratt DE, Sun Y, et al
   Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
   Eur Urol. 2024 Apr 2:S0302-2838(24)02239-5. doi: 10.1016/j.eururo.2024.
   PubMed         Abstract available
   
   
8. ENGLMAN C, Maffei D, Allen C, Kirkham A, et al
   PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
   Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024.
   PubMed         Abstract available
   
   

   
   Int J Radiat Oncol Biol Phys

9. MAITRE P, Maheshwari G, Sarkar J, Singh P, et al
   Late urinary toxicity and QOL with pelvic radiotherapy for high-risk prostate cancer: Dose-effect relations in the POP-RT randomized phase III trial.
   Int J Radiat Oncol Biol Phys. 2024 Mar 27:S0360-3016(24)00439.
   PubMed         Abstract available
   
   

   
   Int J Urol

10. YAMAMOTO Y, Nonomura N
    Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
    Int J Urol. 2024 Apr 4. doi: 10.1111/iju.15458.
    PubMed        
    
    
11. URABE F, Sumiyoshi T, Tashiro K, Goto T, et al
    Prostate cancer and liquid biopsies: Clinical applications and challenges.
    Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15441.
    PubMed         Abstract available
    
    
12. GOTO Y
    Editorial Comment on Prostate cancer and liquid biopsies: Clinical applications and challenges.
    Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15456.
    PubMed        
    
    

    
    J Nucl Med

13. SHI J, Li D, Chen M, Fu Y, et al
    The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
    J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
    PubMed         Abstract available
    
    
14. HARDIANSYAH D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, et al
    Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [(177)Lu]Lu-PSMA-617 Therapy.
    J Nucl Med. 2024;65:566-572.
    PubMed         Abstract available
    
    
15. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    PubMed         Abstract available
    
    

    
    Oncogene

16. CHEN M, Zou C, Tian Y, Li W, et al
    An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.
    Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011.
    PubMed         Abstract available
    
    

    
    Oncol Rep

17. HSIA YJ, Lin ZM, Zhang T, Chou TC, et al
    Butyrate increases methylglyoxal production through regulation of the JAK2/Stat3/Nrf2/Glo1 pathway in castration?resistant prostate cancer cells.
    Oncol Rep. 2024;51:71.
    PubMed         Abstract available
    
    

    
    PLoS One

18. FONSECA-ALVES CE, Leis-Filho AF, Lacerda ZA, de Faria Lainetti P, et al
    Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
    PLoS One. 2024;19:e0297043.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

19. HE T, Cheng C, Qiao Y, Cho H, et al
    Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2322563121.
    PubMed         Abstract available
    
    

    
    Prostate

20. GEBRAEL G, Hage Chehade C, Sayegh N, Tripathi N, et al
    Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24696.
    PubMed         Abstract available
    
    
21. KIM J, Park S, Kim S, Ryu S, et al
    Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24700.
    PubMed         Abstract available
    
    
22. KU HC, Cheng E, Cheng CF
    A body shape index (ABSI) but not body mass index (BMI) is associated with prostate cancer-specific mortality: Evidence from the US NHANES database.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24698.
    PubMed         Abstract available
    
    
23. MODLIN IM, Kidd M, Drozdov IA, Boegemann M, et al
    Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
    Prostate. 2024 Apr 3. doi: 10.1002/pros.24704.
    PubMed         Abstract available
    
    
24. MARTELIN N, De Witt B, Chen B, Eschwege P, et al
    Development and validation of an imageless machine-learning algorithm for the initial screening of prostate cancer.
    Prostate. 2024 Apr 4. doi: 10.1002/pros.24703.
    PubMed         Abstract available
    
    

    
    Radiology

25. JEWELL K, Hofman MS, Ong JSL, Levy S, et al
    Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy.
    Radiology. 2024;311:e231703.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.